Taysha Gene Therapies Inc TSHA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
2.57UNCH (UNCH)
Volume
5,630
Close
2.57quote price arrow down-0.01 (-0.39%)
Volume
1,045,992
52 week range
0.50 - 3.89
Loading...
  • Open2.65
  • Day High2.75
  • Day Low2.54
  • Prev Close2.58
  • 52 Week High3.89
  • 52 Week High Date09/05/23
  • 52 Week Low0.50
  • 52 Week Low Date06/26/23

Key Stats

  • Market Cap480.637M
  • Shares Out187.02M
  • 10 Day Average Volume1.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.35
  • YTD % Change45.2

KEY STATS

  • Open2.65
  • Day High2.75
  • Day Low2.54
  • Prev Close2.58
  • 52 Week High3.89
  • 52 Week High Date09/05/23
  • 52 Week Low0.50
  • 52 Week Low Date06/26/23
  • Market Cap480.637M
  • Shares Out187.02M
  • 10 Day Average Volume1.40M
  • Dividend-
  • Dividend Yield-
  • Beta0.35
  • YTD % Change45.2

RATIOS/PROFITABILITY

  • EPS (TTM)-1.37
  • P/E (TTM)-1.88
  • Fwd P/E (NTM)-5.70
  • EBITDA (TTM)-69.912M
  • ROE (TTM)-294.04%
  • Revenue (TTM)15.451M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-722.06%
  • Debt To Equity (MRQ)54.53%

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Taysha Gene Therapies Inc

 

Profile

MORE
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human...
Sean Nolan
Chairman of the Board, Chief Executive Officer
Sukumar Nagendran M.D.
President, Head of Research and Development, Director
Kamran Alam
Chief Financial Officer
Address
3000 Pegasus Park Drive, Suite 1430
Dallas, TX
75247
United States

Top Peers

SYMBOLLASTCHG%CHG
CCCC
C4 Therapeutics Inc
6.74+0.31+4.82%
FULC
Fulcrum Therapeutics Inc
7.75+0.10+1.31%
APLT
Applied Therapeutics Inc
4.76+0.23+5.08%
ITOS
Iteos Therapeutics Inc
11.66+0.17+1.48%
OCS
Oculis Holding AG
12.80-0.12-0.93%